Open AccessEfficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study
Author(s) -
Pankaj Aneja,
Gaurav Bhalla,
Neeti Parvesh,
Kunal Aneja,
K. S. Aneja
Publication year - 2019
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/ijem.ijem_55_19
Subject(s) - canagliflozin , medicine , overweight , type 2 diabetes mellitus , diabetes mellitus , type 2 diabetes , endocrinology , obesity , pediatrics
To assess the efficacy and safety of canagliflozin (CANA, 300 mg/d) in overweight and obese patients with type 2 diabetes mellitus (T2DM).